Coherus Targets $175M LOQTORZI Revenue by 2028Coherus BioSciences announced ambitious commercial expansion plans during its Q4 2025 earnings call, projecting annualized LOQTORZI sales of $175 million by 2028. The biopharmaceutical company is accelerating its market penetration strategy for the drug, which represents a significant portion of its revenue growth trajectory. This projection reflects strong early commercial performance and expanding market adoption across key therapeutic segments. Beyond revenue targets, Coherus demonstrated substantial financial progress by reducing debt by over 90 percent, significantly improving its balance sheet strength and financial flexibility. This debt reduction allows the company to reinvest capital into research, development, and commercial initiatives without the burden of excessive leverage.
